Skip to main content
. 2020 Mar;8(3):188–198. doi: 10.1016/j.jchf.2019.09.011

Table 2.

Change in Mean SBP From Baseline to 1 Month and to 6 Months and Between-Treatment Differences in SBP, Overall, and in Each SBP Category

Baseline SBP Category Baseline to 1 Month
Baseline to 6 Months
Placebo MRA Difference Placebo MRA Difference
≤105 mm Hg 8.9 ± 15.1 6.1 ± 13.5 2.8 12.3 ± 16.2 9.6 ± 15.1 2.8
>105 to ≤115 mm Hg 4.2 ± 13.3 2.5 ± 14.5 1.7 6.6 ± 16.4 4.8 ± 15.9 1.7
>115 to ≤125 mm Hg 0.9 ± 13.1 0.2 ± 14.5 0.7 2.9 ± 15.0 2.4 ± 15.8 0.4
>125 to ≤135 mm Hg −3.1 ± 14.3 −4.9 ± 13.4 1.8 −0.9 ± 16.4 −3.7 ± 14.0 2.9
>135 mm Hg −10.0 ± 16.6 −11.9 ± 17.7 1.8 −9.3 ± 18.6 −13.0 ± 18.0 3.6
Overall −0.5 ± 15.9 −2.4 ± 16.3 1.9 1.4 ± 18.1 −1.2 ± 17.9 2.6

Values are mean ± SD changes in SBP.

MRA = mineralocorticoid receptor antagonist; SBP = systolic blood pressure.